Deferred Tax Assets, Valuation Allowance of Arcus Biosciences, Inc. from 31 Dec 2017 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Arcus Biosciences, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2017 to 31 Dec 2024.
  • Arcus Biosciences, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $316,000,000, a 36% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Arcus Biosciences, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $316,000,000 +$83,000,000 +36% 31 Dec 2024 10-K 25 Feb 2025 2024 FY
Q4 2023 $233,000,000 +$83,000,000 +55% 31 Dec 2023 10-K 25 Feb 2025 2024 FY
Q4 2022 $150,000,000 +$67,000,000 +81% 31 Dec 2022 10-K 21 Feb 2024 2023 FY
Q4 2021 $83,000,000 -$1,227,000 -1.5% 31 Dec 2021 10-K 28 Feb 2023 2022 FY
Q4 2020 $84,227,000 +$33,807,000 +67% 31 Dec 2020 10-K 23 Feb 2022 2021 FY
Q4 2019 $50,420,000 +$19,682,000 +64% 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q4 2018 $30,738,000 +$12,150,000 +65% 31 Dec 2018 10-K 05 Mar 2020 2019 FY
Q4 2017 $18,588,000 31 Dec 2017 10-K 05 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.